

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Multiple sclerosis: update

2 List of modelling questions

| Review questions by scope area | What is the clinical and cost effectiveness of pharmacological interventions for mobility in people with MS? |
|--|--|
| Population | Adults with MS with walking disability (EDSS scores 4-7). |
| Interventions and comparators considered for inclusion | Fampridine 10mg twice daily + usual care Usual care |
| Time horizon | 5 years |
| Perspective | NHS and PSS (costs and outcomes) |
| Outcomes | Cost per QALY (health outcomes including: treatment response, adverse events, treatment discontinuation, disease progression using timed 25 foot walk test as measure, and death). |
| Type of analysis | CUA |
| Modelling software | Excel |
| Issues to note | Sensitivity analyses undertaken for key inputs and threshold analyses on unit cost of fampridine. Commercially confidential data provided by Biogen, manufacturer of fampridine, for some of the model data inputs. As a result, some of the results of the analysis cannot be published in full. |